{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:46:10Z","timestamp":1788965170995,"version":"build-2803163510"},"reference-count":99,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>\n                    Breast cancer remains the most prevalent malignancy among women worldwide, and its molecular subtypes display marked differences in clinical outcomes and therapeutic responses. Increasing evidence highlights the critical roles of myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment, where they orchestrate immune evasion, promote metastasis, and contribute to therapy resistance. However, most current studies primarily focus on triple-negative breast cancer (TNBC), while systematic insights into the abundance, subset distribution, and functional heterogeneity of MDSCs in Luminal and HER2\n                    <jats:sup>+<\/jats:sup>\n                    subtypes remain limited. This review synthesizes recent advances on major MDSC programs and highlights subtype-associated differences in their distribution patterns, immunosuppressive mechanisms, and clinical relevance across TNBC, HER2\n                    <jats:sup>+<\/jats:sup>\n                    , and HR\n                    <jats:sup>+<\/jats:sup>\n                    \/Luminal breast cancer. We further discuss how these subtype-linked myeloid states may influence key therapeutic outcomes, including pathological complete response following neoadjuvant therapy, heterogeneity of benefit from immunotherapy-based combinations, and the emergence of treatment resistance. In addition, we summarize emerging single-cell and spatial omics approaches that refine MDSC classification and enable\n                    <jats:italic>in situ<\/jats:italic>\n                    mapping of myeloid\u2013lymphocyte organization. Finally, we outline mechanism-guided therapeutic strategies targeting MDSCs\u2014encompassing recruitment\/trafficking blockade, inhibition of suppressive metabolic effector pathways, and myeloid ecosystem remodeling\/reprogramming\u2014to support subtype-tailored precision immunotherapy in breast cancer. This review is intended for researchers in tumor immunology and cancer biology, clinicians and translational medicine professionals, as well as graduate students or early-career scholars interested in immunosuppressive cells and breast cancer.\n                  <\/jats:p>","DOI":"10.7717\/peerj.20937","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:00:22Z","timestamp":1776067222000},"page":"e20937","source":"Crossref","is-referenced-by-count":4,"title":["Subtype-specific heterogeneity of myeloid-derived suppressor cells in breast cancer: current insights and future directions"],"prefix":"10.7717","volume":"14","author":[{"given":"Biyao","family":"Gong","sequence":"first","affiliation":[{"name":"Jiangxi University of Traditional Chinese Medicine, NanChang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixiang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Jiangxi University of Traditional Chinese Medicine, NanChang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"10.7717\/peerj.20937\/ref-1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/s41379-019-0270-4","article-title":"Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer","volume":"32","author":"Abubakar","year":"2019","journal-title":"Modern Pathology"},{"key":"10.7717\/peerj.20937\/ref-2","doi-asserted-by":"publisher","first-page":"1302587","DOI":"10.3389\/fimmu.2024.1302587","article-title":"Cellular interactions in tumor microenvironment during breast cancer progression: new frontiers and implications for novel therapeutics","volume":"15","author":"Akinsipe","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"44","key":"10.7717\/peerj.20937\/ref-3","doi-asserted-by":"publisher","first-page":"eaay6017","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Science Immunology"},{"key":"10.7717\/peerj.20937\/ref-4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"key":"10.7717\/peerj.20937\/ref-5","doi-asserted-by":"publisher","first-page":"e0127028","DOI":"10.1371\/journal.pone.0127028","article-title":"Systemic monocytic-MDSCs are generated from monocytes and correlate with disease progression in breast cancer patients","volume":"10","author":"Bergenfelz","year":"2015","journal-title":"PLOS ONE"},{"key":"10.7717\/peerj.20937\/ref-6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fonc.2020.00109","article-title":"The generation and identity of human myeloid-derived suppressor cells","volume":"10","author":"Bergenfelz","year":"2020","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.20937\/ref-7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.20937\/ref-8","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nature Communications"},{"key":"10.7717\/peerj.20937\/ref-9","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.3390\/cancers13246293","article-title":"Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy","volume":"13","author":"Bullock","year":"2021","journal-title":"Cancers"},{"key":"10.7717\/peerj.20937\/ref-10","doi-asserted-by":"publisher","first-page":"1340764","DOI":"10.3389\/fphar.2024.1340764","article-title":"Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy","volume":"15","author":"Cao","year":"2024","journal-title":"Frontiers in Pharmacology"},{"key":"10.7717\/peerj.20937\/ref-11","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells9081785","article-title":"Role of tumor-associated myeloid cells in breast cancer","volume":"9","author":"Cha","year":"2020","journal-title":"Cells"},{"key":"10.7717\/peerj.20937\/ref-12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","article-title":"Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion","volume":"430","author":"Chaganty","year":"2018","journal-title":"Cancer Letters"},{"key":"10.7717\/peerj.20937\/ref-13","doi-asserted-by":"publisher","DOI":"10.1159\/000549018","article-title":"Anti-HER2\/Neu antibody therapy inhibits HER2+ breast cancer by blocking myeloid-derived suppressor cell activity","author":"Choi","year":"2025","journal-title":"Oncology Research and Treatment"},{"key":"10.7717\/peerj.20937\/ref-14","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1158\/2326-6066.Cir-18-0070","article-title":"Entinostat converts immune-resistant breast and pancreatic cancers into checkpoint-responsive tumors by reprogramming tumor-infiltrating MDSCs","volume":"6","author":"Christmas","year":"2018","journal-title":"Cancer Immunology Research"},{"key":"10.7717\/peerj.20937\/ref-15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies\u2013improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.7717\/peerj.20937\/ref-16","doi-asserted-by":"publisher","first-page":"aaf8943","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Science Immunology"},{"key":"10.7717\/peerj.20937\/ref-17","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3389\/fimmu.2024.1355769","article-title":"EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells","volume":"15","author":"Cuenca-Escalona","year":"2024","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ccell.2025.01.002","article-title":"Dynamics of molecular heterogeneity in high-risk luminal breast cancer\u2014from intrinsic to adaptive subtyping","volume":"43","author":"Denkert","year":"2025","journal-title":"Cancer Cell"},{"key":"10.7717\/peerj.20937\/ref-19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4274\/ejbh.galenos.2025.2024-10-2","article-title":"Prognostic significance and molecular classification of triple negative breast cancer: a systematic review","volume":"21","author":"Dogra","year":"2025","journal-title":"European Journal of Breast Health"},{"issue":"21","key":"10.7717\/peerj.20937\/ref-20","doi-asserted-by":"publisher","first-page":"e94296","DOI":"10.1172\/jci.insight.94296","article-title":"Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer","volume":"2","author":"Dominguez","year":"2017","journal-title":"JCI Insight"},{"key":"10.7717\/peerj.20937\/ref-21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nature Reviews Immunology"},{"key":"10.7717\/peerj.20937\/ref-22","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00262-021-03081-5","article-title":"TGF-\u03b2 orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer","volume":"71","author":"Gneo","year":"2022","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.7717\/peerj.20937\/ref-23","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Annals of Oncology"},{"key":"10.7717\/peerj.20937\/ref-24","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.3892\/ol.2017.6305","article-title":"Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer","volume":"14","author":"Gonda","year":"2017","journal-title":"Oncology Letters"},{"key":"10.7717\/peerj.20937\/ref-25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.7717\/peerj.20937\/ref-26","doi-asserted-by":"publisher","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid cell-derived arginase in cancer immune response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-27","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"10.7717\/peerj.20937\/ref-28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers13020210","article-title":"The functional crosstalk between myeloid-derived suppressor cells and regulatory T Cells within the immunosuppressive tumor microenvironment","volume":"13","author":"Haist","year":"2021","journal-title":"Cancers"},{"key":"10.7717\/peerj.20937\/ref-29","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.semcancer.2017.11.003","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies","volume":"52","author":"Hammerl","year":"2018","journal-title":"Seminars in Cancer Biology"},{"key":"10.7717\/peerj.20937\/ref-30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Molecular Cancer"},{"key":"10.7717\/peerj.20937\/ref-31","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13058-019-1114-3","article-title":"CXCL17-derived CD11b(+)Gr-1(+) myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB","volume":"21","author":"Hsu","year":"2019","journal-title":"Breast Cancer Research"},{"key":"10.7717\/peerj.20937\/ref-32","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13046-025-03454-z","article-title":"Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer","volume":"44","author":"Huang","year":"2025","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.7717\/peerj.20937\/ref-33","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Therapy"},{"key":"10.7717\/peerj.20937\/ref-34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","article-title":"Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy","volume":"44","author":"Imani","year":"2025","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10.7717\/peerj.20937\/ref-35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4137\/cmo.S18006","article-title":"Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information","volume":"8","author":"Inic","year":"2014","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"10.7717\/peerj.20937\/ref-36","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","article-title":"Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics","volume":"53","author":"Jiang","year":"2025","journal-title":"Nucleic Acids Research"},{"issue":"24","key":"10.7717\/peerj.20937\/ref-37","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.3390\/cancers17244003","article-title":"The molecular landscape and utility of multiomic analyses in triple-negative breast cancer: further subtyping and exploring novel biomarkers and therapeutic targets","volume":"17","author":"Juan","year":"2025","journal-title":"Cancers"},{"key":"10.7717\/peerj.20937\/ref-38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3857\/roj.2019.00640","article-title":"The emerging role of myeloid-derived suppressor cells in radiotherapy","volume":"38","author":"Kang","year":"2020","journal-title":"Radiotherapy and Oncology Journal"},{"key":"10.7717\/peerj.20937\/ref-39","doi-asserted-by":"publisher","first-page":"557586","DOI":"10.3389\/fimmu.2020.557586","article-title":"The development and homing of myeloid-derived suppressor cells: from a two-stage model to a multistep narrative","volume":"11","author":"Karin","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-40","doi-asserted-by":"publisher","first-page":"109366","DOI":"10.1016\/j.isci.2024.109366","article-title":"\u0394Np63 regulates MDSC survival and metabolism in triple-negative breast cancer","volume":"27","author":"Kim","year":"2024","journal-title":"iScience"},{"issue":"10","key":"10.7717\/peerj.20937\/ref-41","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.3390\/cancers17101674","article-title":"The CXCL1-CXCR2 axis as a component of therapy resistance, a source of side effects in cancer treatment, and a therapeutic target","volume":"17","author":"Korbecki","year":"2025","journal-title":"Cancers"},{"issue":"4","key":"10.7717\/peerj.20937\/ref-42","first-page":"1045","article-title":"The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies","volume":"10","author":"Kreutzfeldt","year":"2020","journal-title":"American Journal of Cancer Research"},{"key":"10.7717\/peerj.20937\/ref-43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/mi.2024.170","article-title":"Myeloid-derived suppressor cells as targets of emerging therapies and nanotherapies (review)","volume":"4","author":"Kumar","year":"2024","journal-title":"Med International"},{"key":"10.7717\/peerj.20937\/ref-44","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1172\/jci99673","article-title":"\u0394Np63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer","volume":"128","author":"Kumar","year":"2018","journal-title":"Journal of Clinical Investigation"},{"key":"10.7717\/peerj.20937\/ref-45","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends in Immunology"},{"key":"10.7717\/peerj.20937\/ref-46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","article-title":"Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer","volume":"23","author":"Kundu","year":"2024","journal-title":"Molecular Cancer"},{"key":"10.7717\/peerj.20937\/ref-47","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.molmed.2023.09.003","article-title":"CXCR2 chemokine receptor\u2014a master regulator in cancer and physiology","volume":"30","author":"Lazennec","year":"2024","journal-title":"Trends in Molecular Medicine"},{"issue":"19","key":"10.7717\/peerj.20937\/ref-48","doi-asserted-by":"publisher","first-page":"9714","DOI":"10.3390\/ijms26199714","article-title":"Triple-negative breast cancer unveiled: bridging science, treatment strategy, and economic aspects","volume":"26","author":"Lebedeva","year":"2025","journal-title":"International Journal of Molecular Sciences"},{"key":"10.7717\/peerj.20937\/ref-49","doi-asserted-by":"publisher","first-page":"11795549211035540","DOI":"10.1177\/11795549211035540","article-title":"Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects","volume":"15","author":"Li","year":"2021","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"10.7717\/peerj.20937\/ref-50","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.7717\/peerj.20937\/ref-51","doi-asserted-by":"publisher","first-page":"754196","DOI":"10.3389\/fimmu.2021.754196","article-title":"Targeting myeloid-derived suppressor cells to enhance the antitumor efficacy of immune checkpoint blockade therapy","volume":"12","author":"Li","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-52","doi-asserted-by":"publisher","first-page":"1199273","DOI":"10.3389\/fimmu.2023.1199273","article-title":"MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target","volume":"14","author":"Liu","year":"2023","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-53","doi-asserted-by":"publisher","first-page":"e3003299","DOI":"10.1371\/journal.pbio.3003299","article-title":"Decoding metastatic microenvironments through single-cell omics reveals new insights into niche dynamics and tumor evolution","volume":"23","author":"Liu","year":"2025","journal-title":"PLOS Biology"},{"key":"10.7717\/peerj.20937\/ref-54","doi-asserted-by":"publisher","first-page":"e24720","DOI":"10.4161\/onci.24720","article-title":"Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy","volume":"2","author":"Loi","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.7717\/peerj.20937\/ref-55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40164-024-00505-7","article-title":"Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion","volume":"13","author":"Lu","year":"2024","journal-title":"Experimental Hematology & Oncology"},{"key":"10.7717\/peerj.20937\/ref-56","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/jci80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"Journal of Clinical Investigation"},{"key":"10.7717\/peerj.20937\/ref-57","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-019-0504-5","article-title":"Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity","volume":"7","author":"Miret","year":"2019","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"issue":"1","key":"10.7717\/peerj.20937\/ref-58","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3390\/biom15010078","article-title":"Early-stage luminal B-like breast cancer exhibits a more immunosuppressive tumor microenvironment than luminal A-like breast cancer","volume":"15","author":"Moura","year":"2025","journal-title":"Biomolecules"},{"key":"10.7717\/peerj.20937\/ref-59","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1007\/s00262-021-02861-3","article-title":"Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment","volume":"70","author":"O\u2019Brien","year":"2021","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.7717\/peerj.20937\/ref-60","doi-asserted-by":"publisher","first-page":"e009160","DOI":"10.1136\/jitc-2024-009160","article-title":"Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment","volume":"12","author":"O\u2019Connell","year":"2024","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.7717\/peerj.20937\/ref-61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2340\/1651-226x.2024.33008","article-title":"The tumor immune microenvironment in breast cancer progression","volume":"63","author":"Otterlei Fj\u00f8rtoft","year":"2024","journal-title":"Acta Oncologica"},{"key":"10.7717\/peerj.20937\/ref-62","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1158\/1078-0432.Ccr-20-4102","article-title":"Independent validation of the PAM50-based Chemo-Endocrine Score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy","volume":"27","author":"Pascual","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"10.7717\/peerj.20937\/ref-63","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1158\/0008-5472.Can-15-2528","article-title":"Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6\/STAT3 and NO\/NOTCH cross-talk signaling","volume":"76","author":"Peng","year":"2016","journal-title":"Cancer Research and Treatment"},{"key":"10.7717\/peerj.20937\/ref-64","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"24","key":"10.7717\/peerj.20937\/ref-65","doi-asserted-by":"publisher","first-page":"6352","DOI":"10.3390\/cancers13246352","article-title":"Impact of immune cell heterogeneity on HER2+ breast cancer prognosis and response to therapy","volume":"13","author":"Perrone","year":"2021","journal-title":"Cancers"},{"key":"10.7717\/peerj.20937\/ref-66","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1479-5876-11-307","article-title":"Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients","volume":"11","author":"Petricevic","year":"2013","journal-title":"Journal of Translational Medicine"},{"key":"10.7717\/peerj.20937\/ref-67","doi-asserted-by":"publisher","first-page":"101380","DOI":"10.1016\/j.xcrm.2023.101380","article-title":"Surface CD52, CD84, and PTGER2 mark mature PMN-MDSCs from cancer patients and G-CSF-treated donors","volume":"5","author":"Pettinella","year":"2024","journal-title":"Cell Reports Medicine"},{"key":"10.7717\/peerj.20937\/ref-68","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/2159-8290.Cd-24-1208","article-title":"Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype","volume":"15","author":"Pozniak","year":"2025","journal-title":"Cancer Discovery"},{"key":"10.7717\/peerj.20937\/ref-69","doi-asserted-by":"publisher","first-page":"8905","DOI":"10.3390\/ijms21238905","article-title":"Novel miRNA targets and therapies in the triple-negative breast cancer microenvironment: an emerging hope for a challenging disease","volume":"21","author":"Qattan","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"issue":"24","key":"10.7717\/peerj.20937\/ref-70","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.3390\/cancers17243987","article-title":"Modulation of the tumour microenvironment by HER2 in oesophagogastric adenocarcinoma: implications for tumour progression, therapeutic resistance, and clinicopathological outcomes","volume":"17","author":"Raftery","year":"2025","journal-title":"Cancers"},{"issue":"23","key":"10.7717\/peerj.20937\/ref-71","doi-asserted-by":"publisher","first-page":"6012","DOI":"10.3390\/cancers13236012","article-title":"The immune landscape of breast cancer: strategies for overcoming immunotherapy resistance","volume":"13","author":"Retecki","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.7717\/peerj.20937\/ref-72","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.3390\/biomedicines13081945","article-title":"Cytokine networks in triple-negative breast cancer: mechanisms, therapeutic targets, and emerging strategies","volume":"13","author":"Rosado-Sanz","year":"2025","journal-title":"Biomedicines"},{"key":"10.7717\/peerj.20937\/ref-73","doi-asserted-by":"publisher","first-page":"257","DOI":"10.31557\/APJCP.2024.25.1.257","article-title":"Phenotypic analysis of circulating myeloid derived suppressor cells and their subpopulations in Egyptian females with breast cancer: a single-centre case-control study","volume":"25","author":"Saed","year":"2024","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.7717\/peerj.20937\/ref-74","doi-asserted-by":"publisher","first-page":"1170264","DOI":"10.3389\/fonc.2023.1170264","article-title":"The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity","volume":"13","author":"Salemme","year":"2023","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.7717\/peerj.20937\/ref-75","doi-asserted-by":"publisher","first-page":"e178146","DOI":"10.1172\/jci.insight.178146","article-title":"Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages","volume":"10","author":"Sato","year":"2025","journal-title":"JCI Insight"},{"key":"10.7717\/peerj.20937\/ref-76","doi-asserted-by":"publisher","first-page":"39","DOI":"10.18632\/oncotarget.11352","article-title":"Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies","volume":"7","author":"Shou","year":"2016","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.20937\/ref-77","doi-asserted-by":"publisher","first-page":"1956143","DOI":"10.1080\/2162402x.2021.1956143","article-title":"Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma","volume":"10","author":"Sosnowska","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.7717\/peerj.20937\/ref-78","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"The Journal for ImmunoTherapy of Cancer"},{"key":"10.7717\/peerj.20937\/ref-79","doi-asserted-by":"publisher","DOI":"10.1172\/jci145296","article-title":"Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment","volume":"131","author":"Su","year":"2021","journal-title":"Journal of Clinical Investigation"},{"key":"10.7717\/peerj.20937\/ref-80","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.20937\/ref-81","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","article-title":"Targeting HER2-positive breast cancer: advances and future directions","volume":"22","author":"Swain","year":"2023","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.7717\/peerj.20937\/ref-82","doi-asserted-by":"publisher","first-page":"779786","DOI":"10.3389\/fonc.2022.779786","article-title":"Potential predictive and prognostic value of biomarkers related to immune checkpoint inhibitor therapy of triple-negative breast cancer","volume":"12","author":"Tan","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"7","key":"10.7717\/peerj.20937\/ref-83","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3390\/cancers13071511","article-title":"Targeting the IL-6\/STAT3 signalling cascade to reverse tamoxifen resistance in estrogen receptor positive breast cancer","volume":"13","author":"Tsoi","year":"2021","journal-title":"Cancers"},{"key":"10.7717\/peerj.20937\/ref-84","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1172\/jci60083","article-title":"STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients","volume":"123","author":"Vasquez-Dunddel","year":"2013","journal-title":"Journal of Clinical Investigation"},{"key":"10.7717\/peerj.20937\/ref-85","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"Von Minckwitz","year":"2017","journal-title":"The New England Journal of Medicine"},{"key":"10.7717\/peerj.20937\/ref-86","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.7717\/peerj.20937\/ref-87","doi-asserted-by":"publisher","first-page":"e22039","DOI":"10.1002\/jbt.22039","article-title":"Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1\u03b1","volume":"32","author":"Wang","year":"2018","journal-title":"Journal of Biochemical and Molecular Toxicology"},{"key":"10.7717\/peerj.20937\/ref-88","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3389\/fimmu.2018.01310","article-title":"Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors","volume":"9","author":"Weber","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-89","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00262-017-2038-3","article-title":"Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer","volume":"66","author":"Wesolowski","year":"2017","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.7717\/peerj.20937\/ref-90","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20937\/ref-91","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","article-title":"Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.20937\/ref-92","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.3389\/fimmu.2020.01371","article-title":"Myeloid-derived suppressor cells in tumors: from mechanisms to antigen specificity and microenvironmental regulation","volume":"11","author":"Yang","year":"2020","journal-title":"Frontiers in Immunology"},{"key":"10.7717\/peerj.20937\/ref-93","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","article-title":"Recent progress in immune evasion mechanisms of triple-negative breast cancer","volume":"23","author":"Yang","year":"2025","journal-title":"Journal of Translational Medicine"},{"key":"10.7717\/peerj.20937\/ref-94","doi-asserted-by":"publisher","first-page":"412","DOI":"10.5306\/wjco.v5.i3.412","article-title":"Biological subtypes of breast cancer: prognostic and therapeutic implications","volume":"5","author":"Yersal","year":"2014","journal-title":"World Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20937\/ref-95","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-023-01337-3","article-title":"PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.7717\/peerj.20937\/ref-96","doi-asserted-by":"publisher","first-page":"101498","DOI":"10.1016\/j.mcp.2019.101498","article-title":"Lung resided monocytic myeloid-derived suppressor cells contribute to premetastatic niche formation by enhancing MMP-9 expression","volume":"50","author":"Zhang","year":"2020","journal-title":"Molecular and Cellular Probes"},{"key":"10.7717\/peerj.20937\/ref-97","doi-asserted-by":"publisher","first-page":"112617","DOI":"10.1016\/j.mce.2025.112617","article-title":"Breaking immune evasion in breast cancer by targeting COX-2\/PGE2 pathway","volume":"608","author":"Zheng","year":"2025","journal-title":"Molecular and Cellular Endocrinology"},{"key":"10.7717\/peerj.20937\/ref-98","doi-asserted-by":"publisher","first-page":"70","DOI":"10.18632\/oncotarget.23020","article-title":"CXCR2 MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"10.7717\/peerj.20937\/ref-99","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.Can-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Research"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20937.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20937.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:00:24Z","timestamp":1776067224000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":99,"alternative-id":["10.7717\/peerj.20937"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20937","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"e20937"}}